Novartis also reiterated its focused approach to capital allocation, including the ongoing $15 billion share buy-back announced in July 2023 and to continue paying an annual dividend, up from the CHF …
Read Full Story at source (may require registration)
- What is Meant by “Discovery” in Sales? A Strategy for Building Trust and Driving Conversions - March 12, 2025
- How to Sell a Small Business: A Starter Guide for Business Owners - February 3, 2025
- European Shares Drift Lower Amid France’s Debt Woes - November 27, 2024